It has been used safely and effectively for decades as a recognized treatment for drug-resistant epilepsy (DRE) [2,3,4], in GLUT1-Deficiency Syndrome (GLUT1-DS) [5,6] and in pyruvate dehydrogenase complex deficiency (PDCD) [7,8]. Here, SLC2A1 is linked to Dravet syndrome.